TEGAR CAR-T (Baylor College of Medicine)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameTEGAR CAR-T (Baylor College of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Glypican-3

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, HepatocellularHepatoblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBaylor College Of Medicine

Active IndicationsN/A

Inactive IndicationsCarcinoma, HepatocellularHepatoblastoma

Other Information

ATC CodeN/A